No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Buy Rating Justified: Altimmune's Pemvidutide Shows Best-in-Class Potential for Obesity and MASH
Altimmune First Quarter 2024 Earnings: US$0.34 Loss per Share (Vs US$0.40 Loss in 1Q 2023)
Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript
Altimmune Inc (ALT) Reports Q1 2024 Financials: A Detailed Review
Buy Rating Affirmed for Altimmune on Pemvidutide's Potential and Strategic Advancements
No Data
104714243OP : Great assessment of this awesome potential